<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>the akampioneer</title>
	<atom:link href="http://akampioneer.com/feed" rel="self" type="application/rss+xml" />
	<link>http://akampioneer.com</link>
	<description></description>
	<lastBuildDate>Thu, 29 Jul 2010 13:19:09 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Food for Thought: The Challenges of Investing in Science-Based Innovation</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-the-challenges-of-investing-in-science-based-innovation.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-the-challenges-of-investing-in-science-based-innovation.html#comments</comments>
		<pubDate>Thu, 29 Jul 2010 13:19:09 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[Harvard Business School]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investing]]></category>
		<category><![CDATA[long-term success]]></category>
		<category><![CDATA[metrics]]></category>
		<category><![CDATA[science-based]]></category>
		<category><![CDATA[vicky l. sato]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=344</guid>
		<description><![CDATA[What are the rules of investing in science-based innovation? How much long-term thinking does it take to get through tightened markets and economic downturns? These questions are at the core of Vicki L. Sato´s research, who is a Professor of Management Practice in the Technology and Operations Management unit at Harvard Business School. In addition, [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-the-challenges-of-investing-in-science-based-innovation.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Food for Thought: Lessons from a Start-up Nation</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-lessons-from-a-start-up-nation.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-lessons-from-a-start-up-nation.html#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:47:43 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[corporate culture]]></category>
		<category><![CDATA[Dan Senor]]></category>
		<category><![CDATA[entrepreneurship]]></category>
		<category><![CDATA[Israel]]></category>
		<category><![CDATA[Saul Singer]]></category>
		<category><![CDATA[start-up]]></category>
		<category><![CDATA[venture capital]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=465</guid>
		<description><![CDATA[&#8220;Start-up Nation&#8221; by Dan Senor and Saul Singer addresses the trillion-dollar question: How is it that a country of a mere 7.1 million people has per capita venture capital investments 2.5 times greater than in the US (more than 30 times greater than in Europe), the highest density of high tech start-ups in the world [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-lessons-from-a-start-up-nation.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: MediGene Sells Full European Rights for Eligard® to Astellas for EUR 25 Million and Ongoing Royalties</title>
		<link>http://akampioneer.com/company-news/company-news-medigene-sells-full-european-rights-for-eligard%c2%ae-to-astellas-for-eur-25-million-and-ongoing-royalties.html</link>
		<comments>http://akampioneer.com/company-news/company-news-medigene-sells-full-european-rights-for-eligard%c2%ae-to-astellas-for-eur-25-million-and-ongoing-royalties.html#comments</comments>
		<pubDate>Tue, 20 Jul 2010 13:16:44 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[Astellas Pharma Europe]]></category>
		<category><![CDATA[Eligard]]></category>
		<category><![CDATA[MediGene]]></category>
		<category><![CDATA[product rights]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=455</guid>
		<description><![CDATA[MediGene AG (Frankfurt, Prime Standard, MDG, TecDAX) has announced the sale of full  European marketing and distribution rights to Eligard® (leuprolide acetate, for  the treatment of hormone-dependent prostate cancer) to Astellas Pharma Europe  Ltd. (London, &#8220;Astellas&#8221;), previously MediGene&#8217;s European marketing partner for  Eligard®. Astellas will make one-off  payments totalling EUR [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-medigene-sells-full-european-rights-for-eligard%c2%ae-to-astellas-for-eur-25-million-and-ongoing-royalties.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Micromet&#8217;s BiTE Antibodies Overcome Cancer Cell Resistance</title>
		<link>http://akampioneer.com/company-news/company-news-micromets-bite-antibodies-overcome-cancer-cell-resistance.html</link>
		<comments>http://akampioneer.com/company-news/company-news-micromets-bite-antibodies-overcome-cancer-cell-resistance.html#comments</comments>
		<pubDate>Mon, 05 Jul 2010 07:17:03 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[antibodies]]></category>
		<category><![CDATA[BiTE]]></category>
		<category><![CDATA[BRAF]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[Erbitux]]></category>
		<category><![CDATA[KRAS]]></category>
		<category><![CDATA[life cycle management]]></category>
		<category><![CDATA[Micromet]]></category>
		<category><![CDATA[panitumumab]]></category>
		<category><![CDATA[PNAS]]></category>
		<category><![CDATA[tumor resistance]]></category>
		<category><![CDATA[Vectibix]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=451</guid>
		<description><![CDATA[In several clinical trials, antibody company Micromet has demonstrated outstanding efficacy and safety of its bispecific BiTE antibodies which come with two binding sites: one for a cancer target and a second one for a T cell. As a result, T cells are recruited and guided directly to the tumor cell, initiating cancer cell death [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-micromets-bite-antibodies-overcome-cancer-cell-resistance.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Food for Thought: Finally, a Test for Alzheimer&#8217;s?</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-finally-a-test-for-alzheimers.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-finally-a-test-for-alzheimers.html#comments</comments>
		<pubDate>Thu, 24 Jun 2010 12:41:06 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[Alzheimer's disease]]></category>
		<category><![CDATA[Avid Radiopharmaceuticals]]></category>
		<category><![CDATA[diagnostic test]]></category>
		<category><![CDATA[florbetapir]]></category>
		<category><![CDATA[ICAD]]></category>
		<category><![CDATA[SNM]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=445</guid>
		<description><![CDATA[If the story by a small, Philadelphia-based company called Avid Radiopharmaceuticals communicated earlier this month holds up, there will be a reliable diagnostic test for Alzheimer&#8217;s disease available in a few years.
Such a test not only would change diagnosis but also help develop novel Alzheimer treatments as it would enable clinical researchers to check whether a [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-finally-a-test-for-alzheimers.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Probiodrug Obtains Patent, Expands Boards, Wins Award</title>
		<link>http://akampioneer.com/company-news/company-news-probiodrug-obtains-patent-expands-boards-wins-award.html</link>
		<comments>http://akampioneer.com/company-news/company-news-probiodrug-obtains-patent-expands-boards-wins-award.html#comments</comments>
		<pubDate>Mon, 21 Jun 2010 07:46:14 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[Alzheimer' Disease]]></category>
		<category><![CDATA[Claus Braestrup]]></category>
		<category><![CDATA[Industrial Initiative for Central Germany]]></category>
		<category><![CDATA[IQ Innovationspreis Mitteldeutschland]]></category>
		<category><![CDATA[Lennart Mucke]]></category>
		<category><![CDATA[Probiodrug]]></category>
		<category><![CDATA[PSP 2010]]></category>
		<category><![CDATA[Wirtschaftsinitiative Mitteldeutschland]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=437</guid>
		<description><![CDATA[Alzheimer-specialist Probiodrug AG last week not only obtained a new US patent covering the inhibition of the enzyme glutaminyl cyclase (QC) for the treatment of CNS diseases. The company also announced the appointment of Dr Claus Braestrup, former President &#38; CEO of Lundbeck A/S to Chairman of the Supervisory Board and Prof Dr Lennart Mucke, Director [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-probiodrug-obtains-patent-expands-boards-wins-award.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Micromet Presents Updated Results From Phase 1 and Phase 2 Study of Blinatumomab</title>
		<link>http://akampioneer.com/company-news/company-news-micromet-presents-updated-results-from-phase-1-and-phase-2-study-of-blinatumomab.html</link>
		<comments>http://akampioneer.com/company-news/company-news-micromet-presents-updated-results-from-phase-1-and-phase-2-study-of-blinatumomab.html#comments</comments>
		<pubDate>Mon, 14 Jun 2010 13:35:23 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[15th Annual Congress of the European Hematology Association]]></category>
		<category><![CDATA[blinatumomab]]></category>
		<category><![CDATA[EHA]]></category>
		<category><![CDATA[Micromet]]></category>
		<category><![CDATA[MT103]]></category>
		<category><![CDATA[NASDAQ: MITI]]></category>
		<category><![CDATA[updated clinical data]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=426</guid>
		<description><![CDATA[- Update Presented at the 15th Annual Congress of the European Hematology Association (EHA) -
Micromet, Inc. (NASDAQ: MITI) today announced updated clinical data from a Phase 1 and a Phase 2 trial, respectively, of its lead product blinatumomab (MT103). The data were presented at the 15th Annual Congress of the European Hematology Association (EHA) in [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-micromet-presents-updated-results-from-phase-1-and-phase-2-study-of-blinatumomab.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Food for Thought: The Future of Biosimilars</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-the-future-of-biosimilars.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-the-future-of-biosimilars.html#comments</comments>
		<pubDate>Fri, 11 Jun 2010 13:10:51 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[Adem Koyuncu]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[Christopher Klein]]></category>
		<category><![CDATA[dvfa]]></category>
		<category><![CDATA[EMEA]]></category>
		<category><![CDATA[Falk Ehmann]]></category>
		<category><![CDATA[Frank Pieters]]></category>
		<category><![CDATA[Gertraud Unterrainer]]></category>
		<category><![CDATA[LSP Life Science Partners]]></category>
		<category><![CDATA[Manfred Ruediger]]></category>
		<category><![CDATA[Mayer Brown LLP]]></category>
		<category><![CDATA[ProBioGen]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Society of Investment Professionals in Germany]]></category>
		<category><![CDATA[Teva Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=420</guid>
		<description><![CDATA[On June 8, the Society of Investment Professionals in Germany (DVFA) and its Life Science Committee hosted its annual conference which this time focused on biosimilars. The event covered key scientific topics, regulatory pathways and commercial issues of the market.
While experts agreed that the US will soon follow the EU in establishing a regulatory pathway [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-the-future-of-biosimilars.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Food for Thought: Simply Obscene</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-simply-obscene.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-simply-obscene.html#comments</comments>
		<pubDate>Thu, 10 Jun 2010 15:13:04 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[Alimta]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Der Spiegel]]></category>
		<category><![CDATA[Erbitux]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[Gleevec]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hycamtin]]></category>
		<category><![CDATA[Iressa]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[lymphoma]]></category>
		<category><![CDATA[Mab-Thera]]></category>
		<category><![CDATA[Merck KGaA]]></category>
		<category><![CDATA[Nexava]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharma Mar]]></category>
		<category><![CDATA[Rituximab]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sutent]]></category>
		<category><![CDATA[Tyverb]]></category>
		<category><![CDATA[Xeloda]]></category>
		<category><![CDATA[Yondelis]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=380</guid>
		<description><![CDATA[In a recent article (&#8220;Simply Obscene&#8221;) the influential German news magazine &#8220;Der Spiegel&#8221; (20/2010, May 17, 2010) stated the pharma industry was using &#8220;with the unscrupulousness of a stock jobber&#8221; a loophole in Germany&#8217;s highly regulated health care system to charge extremely high prices for basically useless cancer medications. In particular, the article featured Yondelis by Pharma [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-simply-obscene.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Calendar &amp; Events: Upcoming Conferences</title>
		<link>http://akampioneer.com/calendar-events/calendar-events-upcoming-conferences.html</link>
		<comments>http://akampioneer.com/calendar-events/calendar-events-upcoming-conferences.html#comments</comments>
		<pubDate>Thu, 10 Jun 2010 10:11:08 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Calendar & Events]]></category>
		<category><![CDATA[upcoming events]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=402</guid>
		<description><![CDATA[Please find below a brief summary of upcoming conferences of interest:
June 10-13
EHA &#8211; European Hematology Association Annual Meeting
Barcelona, SpainJune 14-17
Goldman Sachs 31st Annual Global Healthcare Conference
Los Angeles, CA, USA
June 17-18
German Electromobility Congress
Bonn
June 22–23
Fifth Annual Piper Jaffray Europe Conference
London, United Kingdom
June 23-24
ChinaBio Partnering Forum
Shanghai, China
June 28-30
Euro Biotech Forum
Paris, France
]]></description>
		<wfw:commentRss>http://akampioneer.com/calendar-events/calendar-events-upcoming-conferences.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
